Novartis has opened a new 10,000-square-foot manufacturing facility in Carlsbad, California, to produce advanced radioligand therapies (RLTs) for cancer treatment. These innovative therapies combine precision targeting with radioactive particles to attack cancer cells while minimizing damage to healthy tissue.

The new Carlsbad plant marks a key step in Novartis’ plan to strengthen its US manufacturing footprint and expand access to radioligand therapies for patients. The facility will support faster and more efficient delivery of these treatments to patients in the western United States, including Alaska and Hawaii.

This investment is part of Novartis’ larger initiative to scale up its global RLT manufacturing network. The company recently announced a $23 billion expansion plan, which includes building and upgrading 10 facilities across the US to enhance the production and distribution of its cancer medicines.

Radioligand therapy is an emerging frontier in oncology, offering targeted, personalized treatment options for hard-to-treat cancers. Novartis currently markets two FDA-approved RLTs and has a strong pipeline of candidates under development.

By expanding its presence in California, Novartis aims to strengthen supply chain resilience, meet growing demand for cancer therapies, and reinforce its leadership in the radiopharmaceutical space.